← Back to Search

Active tDCS for Psychosis

N/A
Waitlist Available
Led By Ian S Ramsay, PhD
Research Sponsored by University of Minnesota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 3-5 weeks
Awards & highlights

Study Summary

This trial will study whether a noninvasive brain stimulation technique can improve cognitive remediation therapy for people with psychotic disorders.

Eligible Conditions
  • Psychosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 3-5 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 3-5 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Brief Assessment of Cognition in Schizophrenia (BACS) from Baseline to Post-Training
Change in N-Back from Baseline to Post-Training
Change in VRFCAT from Baseline to Post-Training

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Active tDCSActive Control1 Intervention
The active tDCS will be applied at a current of 1-2mA via two saline soaked electrode sponges (3 cm x 4.5 cm) for the first 20 minutes of each CRT session in the active condition.
Group II: Sham tDCSPlacebo Group1 Intervention
In the sham condition, tDCS will be ramped up to 1-2 mA via two saline soaked electrode sponges (3 cm x 4.5 cm) over the first 30 seconds of each CRT session and then turned off.

Find a Location

Who is running the clinical trial?

University of MinnesotaLead Sponsor
1,389 Previous Clinical Trials
1,553,043 Total Patients Enrolled
11 Trials studying Psychosis
1,581 Patients Enrolled for Psychosis
Ian S Ramsay, PhDPrincipal InvestigatorUniversity of Minnesota
~7 spots leftby Jun 2025